What changed today in Metabolic: 20 trial updates, 9 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro and Zepbound for different indications.
Building
- Editorial attention
- Building
- Tracked this week
- 9
- Sources this week
- 5
- Last activity
- 1 day ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Tirzepatide at a glance
- About this topic
- Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly and marketed as Mounjaro and Zepbound for different indications.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or… (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 28, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
- 1 NPHLA briefing on this topic
What’s the latest on Tirzepatide?
1 totalWhat do the official records show?
Primary sources and peer-reviewed research- New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or… (opens the source in a new tab)
Phase 3, Pfizer. Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Tirzepatide; Berobenatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients (opens the source in a new tab)
Nanjing First Hospital, Nanjing Medical University. Conditions: Obesity / Overweight. Interventions: Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: TIRZE-PAP (Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative…) (opens the source in a new tab)
Phase 2/Phase 3, Woolcock Institute of Medical Research. Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide. Investigational: trial-stage therapies are not approved for the use stud…
- New trial registered: Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of… (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity. Interventions: Tirzepatide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight (opens the source in a new tab)
Phase 1, Ascletis Pharma (China) Co., Limited. Conditions: Chronic Weight Management. Interventions: ASC35 Injection B, for subcutaneous use; ASC35 Placebo Injection B, for subcutaneous use; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (opens the source in a new tab)
The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (…
Which clinical trials are being tracked?
All trials- STAY-LEAN: Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
The Cleveland Clinic. Conditions: Obesity. Investigational — not approved for the use studied.
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Regeneron Pharmaceuticals. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Investigational — not approved for the use studied.
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer. Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Investigational — not approved for the use studied.
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
Nanjing First Hospital, Nanjing Medical University. Conditions: Obesity / Overweight. Investigational — not approved for the use studied.
- TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial
Woolcock Institute of Medical Research. Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s (opens the source in a new tab)
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial (opens the source in a new tab)
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes (opens the source in a new tab)
- Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill (opens the source in a new tab)